Clinical Trials Search Results
Results 1-10 of 183 for your search
Show Search Criteria
Your Search Criteria
Category |
Your Selection |
|---|---|
| Primary Cancer Type/Condition: | Bladder Cancer |
Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 1189 locations
Age: 18 years and over
Gender: Male or Female
Location: 1189 locations
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 877 locations
Age: 18 years and over
Gender: Male or Female
Location: 877 locations
Pembrolizumab in Treating Patients with Locally Advanced Bladder Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 753 locations
Age: 18 years and over
Gender: Male or Female
Location: 753 locations
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 434 locations
Age: 18 years and over
Gender: Male or Female
Location: 434 locations
Chemoradiotherapy with or without Atezolizumab in Treating Patients with Localized Muscle Invasive Bladder Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 89 locations
Age: 18 years and over
Gender: Male or Female
Location: 89 locations
Cisplatin and Gemcitabine Hydrochloride with or without ATR Kinase Inhibitor M6620 in Treating Patients with Metastatic Urothelial Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 34 locations
Age: 18 years and over
Gender: Male or Female
Location: 34 locations
Neratinib HER Mutation Basket Study (SUMMIT)
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 25 locations
Age: 18 years and over
Gender: Male or Female
Location: 25 locations
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 25 locations
Age: 18 years and over
Gender: Male or Female
Location: 25 locations
My Pathway: A Study Evaluating Herceptin / Perjeta, Tarceva, Zelboraf / Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 24 locations
Age: 18 years and over
Gender: Male or Female
Location: 24 locations
Sapanisertib in Treating Patients with Locally Advanced or Metastatic Bladder Cancer with TSC1 and / or TSC2 Mutations
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 20 locations
Age: 18 years and over
Gender: Male or Female
Location: 20 locations